FOMO-MRI/FOMO60K

This collection of datasets is released under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license. Each individual dataset within the collection retains its original license, which is reported in the corresponding dataset folder. Some datasets are additionally subject to Data Use Agreements (DUAs), which are reported below and in the relevant dataset folders. Users must comply with the applicable license terms and any associated DUAs.

You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Full license: https://creativecommons.org/licenses/by-nc-sa/4.0/

DUAs:

OASIS Data Use Agreement

The OASIS data are distributed to the greater scientific community under the following terms:

1. User will not use the OASIS datasets, either alone or in concert with any other information, to make any effort to identify or contact individuals who are or may be the sources of the information in the dataset. If User inadvertently receives identifiable information or otherwise identifies a subject, User will immediately notify OASIS and follow OASISs reasonable written instructions, which may include the return or destruction of identifiable information.
2. User is strictly prohibited from generating or using images or comparable representations of the face, head, or body for facial recognition, re-identification, or other purposes that could allow the identities of research participants to be readily ascertained.
3. User will not use or further disclose the OASIS-3 or OASIS-4 except as required by law. User shall not share, distribute, or otherwise make available the OASIS data, in whole or in part, to any third party, including collaborators, without prior written permission from OASIS. All collaborators must independently apply for access and agree to these terms. Additionally, User will not use or further disclose any derivative works or derivative data of the OASIS datasets, in any case in whole or in part, that could be used to reconstruct a facial image. User shall report to OASIS immediately upon Users discovery of any unauthorized use or disclosure not permitted by this Data Use Agreement. User shall provide the following information: (1) the nature of the use or disclosure; (2) the information used or disclosed; (3) the identity of the persons and/or entities that made the use or disclosure; and (4) what corrective action will be taken by User as a result of the use or disclosure. User shall take any other reasonable actions available to it to mitigate any detrimental effects of the use or disclosure.
4. User agrees to implement appropriate administrative, physical, and technical safeguards to protect the OASIS data from unauthorized access, use or disclosure. OASIS data must be stored on secure, access-controlled systems, and only the User authorized under this Data Use Agreement may access the data.
5. OASIS data are provided for non-commercial, academic research purposes only. Any commercial use, including but not limited to the sale of data or commercial consulting, is strictly prohibited without explicit, prior written authorization from OASIS.
6. User agrees to retain OASIS data only for as long as necessary to fulfill the research purposes described in Users application. Upon completion of the research or upon request by OASIS, User will securely destroy or return all copies of the data.
7. User will acknowledge the use of OASIS data and data derived from OASIS data when publicly presenting any results or algorithms that benefitted from their use. Papers, book chapters, books, posters, oral presentations, and all other printed
   and digital presentations of results derived from OASIS data should contain the following:
   • Acknowledgments: Data were provided [in part] by OASIS [insert appropriate OASIS source info]
     (a) OASIS-1: Cross-Sectional: Principal Investigators: D. Marcus, R, Buckner, J, Csernansky J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
     (b) OASIS-2: Longitudinal: Principal Investigators: D. Marcus, R, Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
     (c) OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
     (d) OASIS-3_AV1451: Principal Investigators: T. Benzinger, J. Morris; NIH P30 AG066444, AW00006993. AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
     (e) OASIS-4: Clinical Cohort: Principal Investigators: T. Benzinger, L. Koenig, P. LaMontagne
   • Citation: The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes. An annotated and current list of OASIS publications is available at http://www.oasis- brains.org.
     (a) OASIS-1: Cross-Sectional: https://doi.org/10.1162/jocn.2007.19.9.1498
     (b) OASIS-2: Longitudinal: https://doi.org/10.1162/jocn.2009.21407
     (c) OASIS-3: Longitudinal Multimodal Neuroimaging: https://doi.org/10.1101/2019.12.13.19014902
     (d) OASIS-4: Clinical Cohort: https://doi.org/10.1016/j.nicl.2020.102248
   • All proposed publications or presentations using Florbetapir F18 (AV45) or Flortaucipir F18 (AV1451) PET data must be submitted to Avid Radiopharmaceuticals for review and comment thirty days prior to such presentation or publication for review of intellectual property interests. See Imaging data dictionary for contact information and details.
8. User agree to provide the Knight ADRC with information on Users use of OASIS data, upon request.
9. Failure to abide by these data use terms may result in termination of your right to access and use OASIS data. In the event of breach of this Data Use Agreement, OASIS reserves the right to pursue all remedies available at law or in equity, including but not limited to termination of access, notification of the Users institution, and legal action.

BraTS-GEN Data Use Agreement

You are free to use and/or refer to the BraTS datasets in your own research, provided that you always cite the flagship manuscript (published or pre-published) resulting from the challenge, as well as the following challenge-specific manuscripts:

Dataset:

• Any dataset and/or Med-Perf client
  • Citations Needed
    • A. Karargyris, R. Umeton, M.J. Sheller, A. Aristizabal, J. George, A. Wuest, S. Pati, et al. "Federated benchmarking of medical artificial intelligence with MedPerf". Nature Machine Intelligence. 5:799810 (2023).
    • DOI: https://doi.org/10.1038/s42256-023-00652-2
• BraTS-GLI
  • Citations Needed
    1 U.Baid, et al., The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification, arXiv:2107.02314, 2021.
    2 B. H. Menze, A. Jakab, S. Bauer, J. Kalpathy-Cramer, K. Farahani, J. Kirby, et al. "The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)", IEEE Transactions on Medical Imaging 34(10), 1993-2024 (2015) DOI: https://doi.org/10.1109 TMI.2014.2377694
    3 S. Bakas, H. Akbari, A. Sotiras, M. Bilello, M. Rozycki, J.S. Kirby, et al., "Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features", Nature Scientific Data, 4:170117 (2017) DOI: https://doi.org/10.1038/sdata.2017.117
    In addition, if there are no restrictions imposed from the journal/conference you submit your paper about citing "Data Citations", please be specific and also cite the following:
    4 S. Bakas, H. Akbari, A. Sotiras, M. Bilello, M. Rozycki, J. Kirby, et al., "Segmentation Labels and Radiomic Features for the Pre-operative Scans of the TCGA-GBM collection", The Cancer Imaging Archive, 2017. DOI: https://doi.org/10.7937/K9/TCIA.2017.KLXWJJ1Q
    5 S. Bakas, H. Akbari, A. Sotiras, M. Bilello, M. Rozycki, J. Kirby, et al., "Segmentation Labels and Radiomic Features for the Pre-operative Scans of the TCGA-LGG collection", The Cancer Imaging Archive, 2017. DOI: https://doi.org/10.7937/K9/TCIA.2017.GJQ7R0EF
• BraTS-MEN
  • Citations Needed
    • arXiv: https://arxiv.org/abs/2305.07642
    • DOI: https://doi.org/10.48550/arXiv.2305.07642
• BraTS-MET
  • Citations Needed
    • arXiv: https://arxiv.org/abs/2306.00838
    • DOI: https://doi.org/10.48550/arXiv.2306.00838
• BraTS-PED
  • Citations Needed
    • arXiv: https://arxiv.org/abs/2305.17033
    • DOI: https://doi.org/10.48550/arXiv.2305.17033
• BraTS-SSA
  • Citations Needed
    1 Adewole M, Rudie JD, Gbadamosi A, et al. The Brain Tumor Segmentation (BraTS) Challenge 2023: Glioma Segmentation in Sub-Saharan Africa Patient Population (BraTS-Africa). arXiv:2305.19369 [eess.IV] (2023).
    • arXiv: https://arxiv.org/abs/2305.19369
    • DOI: https://doi.org/10.48550/arXiv.2305.19369

Note: Challenge participants agree to cite the initial challenge pre publication manuscript (or the final publication manuscript). You will be contacted through your Synapse affiliated email when the manuscript has been released for citation. Note: Use of the BraTS datasets for creating and submitting benchmark results for publication on MLPerf.org is considered non-commercial use. It is further acceptable to republish results published on MLPerf.org, as well as to create unverified benchmark results consistent with the MLPerf.org rules in other locations. Please note that you should always adhere to the BraTS data usage guidelines and cite appropriately the aforementioned publications, as well as to the terms of use required by MLPerf.org.

By requesting access, you agree to the above terms.